By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Developing next-generation complement therapeutics for patients living with severe autoimmune and396K100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States6.24M100.00%